Politics · 1 sources covering this

Moderna stock prices double on claimed mRNA cancer vaccine breakthrough

Stock prices for the American vaccine manufacturer Moderna more than doubled on Wednesday after the company reported successful results from its messenger RNA melanoma cancer vaccine.  The mRNA shot, in combination with Merck’s immunotherapy drug Keytruda, met critical benchmarks in a global late-stage clinical trial of more than 1,100 patients with higher-risk or advanced melanoma […]

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

Washington ExaminerLean R·1h ago
Moderna stock prices double on claimed mRNA cancer vaccine breakthrough
Stock prices for the American vaccine manufacturer Moderna more than doubled on Wednesday after the company reported successful results from its messenger RNA melanoma cancer vaccine.  The mRNA shot, in combination with Merck’s immunotherapy drug Keytruda, met critical benchmarks in a global late-stage clinical trial of more than 1,100 patients with higher-risk or advanced melanoma […]
Read at Washington Examiner →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/8f080e49d06bb65dd877b13511bd991ae1f97b2a"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Moderna stock prices double on claimed mRNA cancer vaccine breakthrough"></iframe>

Moderna stock prices double on claimed mRNA cancer vaccine breakthrough

How 1 sources are covering this